Dova Pharmaceuticals Inc (NASDAQ:DOVA) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price target of $35.67 for the company and are expecting that the company will post ($0.36) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Dova Pharmaceuticals an industry rank of 181 out of 265 based on the ratings given to related companies.
A number of equities research analysts have commented on the stock. BidaskClub upgraded shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, January 13th. Jefferies Group lifted their price objective on shares of Dova Pharmaceuticals to $33.00 and gave the company a “buy” rating in a report on Tuesday, November 28th. Finally, Zacks Investment Research cut shares of Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). During the same period last year, the business posted ($0.41) EPS. research analysts anticipate that Dova Pharmaceuticals will post -1.51 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC acquired a new position in shares of Dova Pharmaceuticals during the second quarter valued at about $43,969,000. Perceptive Advisors LLC grew its holdings in shares of Dova Pharmaceuticals by 2.8% during the third quarter. Perceptive Advisors LLC now owns 1,754,015 shares of the company’s stock valued at $42,587,000 after buying an additional 47,516 shares during the last quarter. Fosun International Ltd grew its holdings in shares of Dova Pharmaceuticals by 9.2% during the third quarter. Fosun International Ltd now owns 710,000 shares of the company’s stock valued at $17,239,000 after buying an additional 60,000 shares during the last quarter. Paulson & CO. Inc. acquired a new position in shares of Dova Pharmaceuticals during the second quarter valued at about $13,856,000. Finally, BlackRock Inc. grew its holdings in shares of Dova Pharmaceuticals by 152.4% during the fourth quarter. BlackRock Inc. now owns 576,799 shares of the company’s stock valued at $16,611,000 after buying an additional 348,290 shares during the last quarter. Hedge funds and other institutional investors own 26.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Zacks: Dova Pharmaceuticals Inc (DOVA) Receives Consensus Recommendation of “Strong Buy” from Analysts” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/12/zacks-dova-pharmaceuticals-inc-dova-receives-consensus-recommendation-of-strong-buy-from-analysts.html.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.